Table 1

mAb therapy targeting cell surface antigens, cytokines, and adhesion molecules and recombinant cytokine therapy in models of immune mediated ocular inflammation and corneal allograft rejection

		Target		References
		Target		Suppression	No effect/ exacerbation
Cell surface	CD4	14, 42, 43, 49,50
	MHC class II	51
	CD8		52
Adhesion targets	ICAM-1/LFA-1	45, 53–57
	VLA-4	56,57
Anti-cytokine mAb	IL-12	46
	TNF-α	47	58–60
RHU cytokine therapy	IL-12	39
	IL-4		61
	TNF-α	40, 41

↵These studies have shown that treatment with such mAb or recombinant cytokine suppresses target organ destruction.
↵These studies have shown no effect or provide evidence of paradoxical effects of therapy in some forms of experimental ocular inflammatory models although generally not experimental models of PSII.